pathology-congress-2017-scientifictracks-abstracts

18 / 18

Page 38
conferenceseries.com
Volume 7, Issue 5 (Suppl) J Clin Exp Pathol
ISSN: 2161-0681 JCEP, an open access journal Pathology Congress 2017
November 13-14, 2017
NOVEMBER 13-14, 2017 OSAKA, JAPAN
14th Asia Pacific Pathology Congress
ALK overexpression in triple negative breast cancer using immunohistochemistry
Zonaira Rathore and Ghazi Zafar
Chughtai Lab, Pakistan
Breast cancer is the most common female malignancy worldwide. Studies have identified different molecular subtypes
including luminal A, luminal B, Her2 positive andTripleNegative Breast Cancer (TNBC) on basis of Immunohistochemistry
(IHC). They have different prognosis and response to adjuvant therapy. Anaplastic Lymphoma Kinase (ALK) is a tyrosine
kinase receptor known to be expressed in many tumors and can be targeted by anti-tyrosine kinase inhibitors. Studies have
shown subset of breast carcinomas to express ALK. The aim of our study is to determine ALK protein overexpression using
IHC on TNBC patients, providing them with a targeted therapy option. A cross-sectional study was performed, on 43 cases
of TNBC of all histologic subtypes retrieved from archives of Chughtai Lab, Lahore, from 1st January 2016 to 30th July 2017,
using non-probability consecutive sampling technique. Mouse anti-human monoclonal antibody against ALK from DAKO
was used. Membranous and/or nuclear staining of ALK in at least 1% of tumor cells was taken as positive. All data was analyzed
through SPSS version 22.0. Our study showed 11 cases (25.6%) to overexpress ALK by immunohistochemistry. Only 1 case
(2.3%) showed cytoplasmic granular positivity along with nuclear staining while 10 cases showed only nuclear pattern of
staining (23.2%). This study concludes that a significant number of cases show ALK overexpression by IHC, predominantly
nuclear. Further studies are required, using In Situ Hybridization (ISH), to confirm ALK gene rearrangement and validate the
significance of nuclear staining of ALK as seen is our study. This subset of patient may benefit from anti-ALK therapy. However
further studies are required to validate the results.
Biography
Zonaira Rathore has obtained her MBBS from King Edward Medical University. Currently she is working as Consultant Histopathologist at Chughtai Lab, Pakistan.
Zonaira Rathore et al., J Clin Exp Pathol 2017, 7:5 (Suppl)
DOI: 10.4172/2161-0681-C1-040